Anas Younes, MD, discusses the current and future state of CAR T-cell therapies and immune checkpoint inhibitors in the landscape of hematologic malignancies.
CMS's initial payment codes for CAR T-cell therapies are opposed by the medical community on the basis that they would be cumbersome to implement and wouldn't reflect the full amount of care delivered to each patient.
Eliminating T cells carrying alpha and beta chains of the T-cell receptor reduced the risk for graft-versus-host-disease while producing "excellent" engraftment kinetics for young patients with acute leukemia who underwent hematopoietic stem cell transplant.
Results from a recent study may show why some patients with chronic lymphocytic leukemia are resistant to tisagenlecleucel, while potentially offering a pathway to enhance patient response.
The FDA has approved tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
Maung Myo Htut, MD, discusses the use of CAR T-cell therapy in multiple myeloma and the potential infusion of immunotherapy into treatment.
An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.
Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia.
Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.
Both prior chemotherapy and a dependence on glycolysis appear to reduce the potential to develop T cells into chimeric antigen receptor T-cell therapy.